お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
721692

ウェアラブルインジェクターの世界市場の予測 ~2023年:オンボディ型・オフボディ型 (輸液ポンプ型)

Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinson's disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 105 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
ウェアラブルインジェクターの世界市場の予測 ~2023年:オンボディ型・オフボディ型 (輸液ポンプ型)
出版日: 2018年10月08日
発行: MarketsandMarkets
ページ情報: 英文 105 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のウェアラブルインジェクターの市場は予測期間中11.1%のCAGR (年間複合成長率) で推移し、2018年の55億7000万米ドルから、2023年には94億1000万米ドルの規模に成長すると予測されています。対象疾患の有病率の拡大、良好な償還環境、技術的進歩などの要因が同市場の成長を推進する見通しです。

当レポートでは、世界のウェアラブルインジェクターの市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、タイプ・治療区分・地域別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

FIGURE 10 WEARABLE INJECTORS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要・産業動向

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 ウェアラブルインジェクター市場の分析・予測:タイプ別

  • イントロダクション
  • オンボディ型
  • オフボディ型

第7章 ウェアラブルインジェクター市場の分析・予測:治療区分別

  • イントロダクション
  • 免疫腫瘍
  • 糖尿病
  • 心血管疾患
  • その他

第8章 ウェアラブルインジェクター市場の分析・予測:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他
  • その他の地域

第9章 競合環境

  • 概要
  • 市場シェア分析
  • 市場シェア分析:治療区分別
  • 競合シナリオ
    • 製品の投入・承認
    • 拡張
    • 合意・提携・協力

第10章 企業プロファイル

  • AMGEN
  • MEDTRONIC PLC
  • INSULET CORPORATION
  • YPSOMED
  • BECTON, DICKINSON AND COMPANY
  • TANDEM DIABETES CARE, INC.
  • UNITED THERAPEUTICS CORPORATION
  • VALERITAS, INC.
  • ENABLE INJECTIONS
  • STEADYMED THERAPEUTICS
  • SENSILE MEDICAL

第11章 付録

図表

LIST OF TABLES

  • TABLE 1: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 2: ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 3: OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 4: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD BILLION)
  • TABLE 5: WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: INSULIN DEVICES AVAILABLE FOR DIABETIC PATIENTS
  • TABLE 7: WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 9: WEARABLE INJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: WEARABLE INJECTORS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 11: NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 12: NORTH AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 13: NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 14: US: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 15: US: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 16: CANADA: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 17: CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 18: RECENT DEVELOPMENTS IN THE WEARABLE INJECTORS MARKET IN EUROPE, 2015-2018
  • TABLE 19: EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: EUROPE: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 21: EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 22: GERMANY: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 23: GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 24: UK: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 25: UK: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 26: FRANCE: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 27: FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 28: ROE: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 29: ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 30: ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 31: ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 32: ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 33: JAPAN: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 34: JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 35: CHINA: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 36: CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 37: INDIA: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 38: INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 39: ROAPAC: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 40: ROAPAC: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 41: CONFERENCES IN AFRICA, BRAZIL, AND THE MIDDLE EAST (2016-2018)
  • TABLE 42: ROW: WEARABLE INJECTORS MARKET, BY THERAPY, 2016-2023 (USD MILLION)
  • TABLE 43: ROW: WEARABLE INJECTORS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 44: PRODUCT LAUNCHES AND APPROVALS
  • TABLE 45: EXPANSIONS
  • TABLE 46: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

LIST OF FIGURES

  • FIGURE 1: WEARABLE INJECTORS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: RESEARCH DESIGN
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: IMMUNO-ONCOLOGY THERAPY SEGMENT TO DOMINATE THE WEARABLE INJECTORS MARKET IN 2018
  • FIGURE 8: ON-BODY INJECTORS TO ACCOUNT FOR THE LARGEST SHARE OF THE WEARABLE INJECTORS MARKET IN 2018
  • FIGURE 9: NORTH AMERICA TO WITNESS THE HIGHEST MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 10: GROWING PREVALENCE OF CHRONIC DISEASES IS DRIVING MARKET GROWTH
  • FIGURE 11: ON-BODY INJECTORS SEGMENT TO DOMINATE THE MARKET IN 2018
  • FIGURE 12: IMMUNO-ONCOLOGY SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2018
  • FIGURE 13: NORTH AMERICA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 14: WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 15: WEARABLE INJECTORS MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 16: WEARABLE INJECTORS MARKET, BY THERAPY, 2018 VS. 2023 (USD BILLION)
  • FIGURE 17: NORTH AMERICA TO COMMAND THE LARGEST MARKET SHARE IN 2018
  • FIGURE 18: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 19: EUROPE: MARKET SNAPSHOT
  • FIGURE 20: ASIA PACIFIC: MARKET SNAPSHOT
  • FIGURE 21: ROW: MARKET SNAPSHOT
  • FIGURE 22: STRATEGIES ADOPTED BY MARKET PLAYERS (2014-2018)
  • FIGURE 23: AMGEN: COMPANY SNAPSHOT (2017)
  • FIGURE 24: MEDTRONIC PLC: COMPANY SNAPSHOT (2017)
  • FIGURE 25: INSULET CORPORATION: COMPANY SNAPSHOT (2017)
  • FIGURE 26: YPSOMED: COMPANY SNAPSHOT (2017)
  • FIGURE 27: BD: COMPANY SNAPSHOT (2017)
  • FIGURE 28: TANDEM DIABETES CARE: COMPANY SNAPSHOT (2017)
  • FIGURE 29: UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2017)
  • FIGURE 30: VALERITAS: COMPANY SNAPSHOT (2017)
目次
Product Code: MD 6659

"The wearable injectors market is projected to grow at a CAGR of 11.1% during the forecast period."

The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from an estimated USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period. The growing prevalence of targeted therapies, favorable reimbursement, and technological advancements in wearable injectors are expected to drive the growth of the wearable injectors market. However, the preference for alternative routes of drug delivery such as pens & autoinjectors is expected to restrain the growth of this market to a certain extent.

"By type, the off-body injectors segment is expected to grow at the highest rate during the forecast period (2018-2023)."

Based on type, the market is segmented into on-body and off-body injectors. The off-body injectors segment is expected to register the highest CAGR during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased demand for off-body injectors.

"By therapy, the cardiovascular diseases segment is expected to witness the highest CAGR during the study period."

Based on therapy, the global wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson's disease, thalassemia, and primary immunodeficiency disorders). The cardiovascular diseases segment is expected to witness the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high burden of CVDs across the globe coupled with the growing availability of wearable injectors for the treatment of CVDs.

"The North American wearable injectors market is expected to grow at the highest CAGR during the forecast period."

North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the US and Canada.

Breakup of primary participants is mentioned below:

  • By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
  • By Designation: C-level - 43%, Director-level - 32%, and Others-25%
  • By Region: North America - 38%, Europe - 23%, Asia Pacific - 29%, and the Row-10%

The key players in the global wearable injectors market are: Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), Valeritas (US), SteadyMed Therapeutics (US), Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).

Research Coverage:

The report analyzes the wearable injectors market and aims at estimating the market size and future growth potential of this market based on various segments such as type, therapy, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the wearable injectors market. The report analyzes the market based on type, therapy, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the wearable injectors market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various wearable injectors across regions
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the wearable injectors market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
      • 2.2.2.1. Key data from primary sources
      • 2.2.2.2. Key industry insights
  • 2.3. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.4. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. WEARABLE INJECTORS: MARKET OVERVIEW
  • 4.2. WEARABLE INJECTORS MARKET, BY TYPE, 2018 VS. 2023
  • 4.3. GEOGRAPHIC ANALYSIS: WEARABLE INJECTORS MARKET, BY THERAPY
  • 4.4. GEOGRAPHIC SNAPSHOT: WEARABLE INJECTORS MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Growing prevalence of chronic diseases
      • 5.2.1.2. Favorable reimbursement scenario in major markets
      • 5.2.1.3. Technological advancements and design development
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Preference for alternative drug delivery modes
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing demand for biologics and mAbs
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Unfavorable reimbursement structure in developing countries

6. WEARABLE INJECTORS MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. ON-BODY INJECTORS
  • 6.3. OFF-BODY INJECTORS

7. WEARABLE INJECTORS MARKET, BY THERAPY

  • 7.1. INTRODUCTION
  • 7.2. IMMUNO-ONCOLOGY
  • 7.3. DIABETES
  • 7.4. CARDIOVASCULAR DISEASES
  • 7.5. OTHER THERAPIES

8. WEARABLE INJECTORS MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. NORTH AMERICA
    • 8.2.1. US
    • 8.2.2. CANADA
  • 8.3. EUROPE
    • 8.3.1. GERMANY
    • 8.3.2. UK
    • 8.3.3. FRANCE
    • 8.3.4. REST OF EUROPE
  • 8.4. ASIA PACIFIC
    • 8.4.1. JAPAN
    • 8.4.2. CHINA
    • 8.4.3. INDIA
    • 8.4.4. ROAPAC
  • 8.5. REST OF THE WORLD

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. MARKET SHARE ANALYSIS
  • 9.3. MARKET SHARE ANALYSIS, BY THERAPY
    • 9.3.1. IMMUNO-ONCOLOGY
    • 9.3.2. AMGEN
    • 9.3.3. DIABETES
    • 9.3.4. MEDTRONIC
    • 9.3.5. INSULET CORPORATION
    • 9.3.6. CARDIOVASCULAR DISEASES
    • 9.3.7. UNITED THERAPEUTICS
  • 9.4. COMPETITIVE SCENARIO
    • 9.4.1. PRODUCT LAUNCHES AND APPROVALS
    • 9.4.2. EXPANSIONS
    • 9.4.3. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

10. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 10.1. AMGEN
  • 10.2. MEDTRONIC PLC
  • 10.3. INSULET CORPORATION
  • 10.4. YPSOMED
  • 10.5. BECTON, DICKINSON AND COMPANY
  • 10.6. TANDEM DIABETES CARE, INC.
  • 10.7. UNITED THERAPEUTICS CORPORATION
  • 10.8. VALERITAS, INC.
  • 10.9. ENABLE INJECTIONS
  • 10.10. STEADYMED THERAPEUTICS
  • 10.11. SENSILE MEDICAL (A PART OF GERRESHEIMER)

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

11. APPENDIX

  • 11.1. DISCUSSION GUIDE
  • 11.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3. AVAILABLE CUSTOMIZATIONS
  • 11.4. RELATED REPORTS
  • 11.5. AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.